Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

Earlier Diagnosis of Melanoma May Soon Become Possible Using T-Rays

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
New imaging technology has great potential to diagnose cancer at its earliest and most treatable stages.

Anis Rahman, PhD, president and chief technology officer of Applied Research & Photonics (Harrisburg, PA, USA), reported that malignant melanoma, the most lethal type of skin cancer, begins in pigment-producing cells located in the deepest part of the epidermis (the outer layer of the skin). Biochemical alterations are key characteristics of cancer occur in the melanocytes a long time before mole-like melanomas appear on the skin.

“Terahertz radiation is ideal for looking beneath the skin and detecting early signs of melanoma,” Dr. Rahman said. “T-rays are different from X-rays, which are ‘ionizing’ radiation that can cause damage. T-rays are a form of nonionizing radiation, like ordinary visible light, but they can be focused harmlessly below into the body and capture biochemical signatures of events like the start of cancer.”

T-rays occupy a position in the spectrum of electromagnetic radiation, which includes visible light and X-rays, between microwaves and infrared rays. One of the benefits of T-rays is that they penetrate only a few millimeters through skin, cloth, and other nonmetallic material.

Dr. Rahman’s research on T-rays was made through donated samples of human skin, suggesting that the technology could be valuable in diagnosing melanoma. In addition to developing T-rays for cancer diagnostics, Dr. Rahman’s team has effectively utilized them to measure the real-time absorption rates and penetration in the outer layer of skin of topically applied drugs—measurements that until now had not been possible.

Dr. Rahman presented his findings at a symposium held at the annual American Chemical Society (ACS) 2013 meeting, held September 11, 2013, in Indianapolis (IN, USA).

Related Links:
Applied Research & Photonics


Channels

Genomics/Proteomics

view channel
Image: The non-active drug is activated when it becomes localized at a site with excessive inflammation (Photo courtesy of Ben-Gurion University of the Negev).

Chimeric Drug Reduces Local Inflammation Without Causing General Immune Suppression

A novel anti-inflammatory drug is based on a chimeric molecule that avoids general immune suppression by being non-active when injected but is converted into an activate agent by leukocytes concentrated... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.